

CorMedix Inc.  
Form 4  
January 02, 2015

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

Check this box  
if no longer  
subject to  
Section 16.  
Form 4 or  
Form 5  
obligations  
may continue.  
See Instruction  
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF  
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

## OMB APPROVAL

OMB  
Number: 3235-0287  
Expires: January 31,  
2005  
Estimated average  
burden hours per  
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**MILBY RANDY**

(Last) (First) (Middle)

**C/O CORMEDIX INC., 745 ROUTE  
202-206, SUITE 303**

(Street)

**BRIDGEWATER, NJ US 08807**

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading  
Symbol  
**CorMedix Inc. [CRMD]**

3. Date of Earliest Transaction  
(Month/Day/Year)  
**12/31/2014**

4. If Amendment, Date Original  
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to  
Issuer

(Check all applicable)

☒ Director ☐ 10% Owner  
☒ Officer (give title below) ☐ Other (specify  
below)

Chief Executive Officer

6. Individual or Joint/Group Filing(Check  
Applicable Line)  
☒ Form filed by One Reporting Person  
☐ Form filed by More than One Reporting  
Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of<br>Security<br>(Instr. 3)                 | 2. Transaction Date<br>(Month/Day/Year) | 2A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 3.<br>Transaction<br>Code<br>(Instr. 8) | 4. Securities Acquired<br>(A) or Disposed of<br>(D)<br>(Instr. 3, 4 and 5) | 5. Amount of<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s)<br>(Instr. 3 and 4) | 6. Ownership<br>Form: Direct<br>(D) or<br>Indirect (I)<br>(Instr. 4) | 7. Nature of<br>Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|-------------------------------------------------------|-----------------------------------------|-------------------------------------------------------------|-----------------------------------------|----------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------|-------------------------------------------------------------------|
| Common<br>Stock,<br>\$0.001 par<br>value per<br>share | 12/31/2014                              |                                                             | P <sup>(1)</sup>                        | 3,272 A                                                                    | \$<br>1.91 46,298                                                                                                  | D                                                                    |                                                                   |
| Common<br>Stock,<br>\$0.001 par<br>value per<br>share |                                         |                                                             |                                         |                                                                            | 196,243                                                                                                            | I <sup>(2)</sup>                                                     | MW<br>Bridges<br>LLC <sup>(2)</sup>                               |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3)                      | 2. Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 4. Transaction<br>Code<br>(Instr. 8) | 5. Number<br>of<br>Derivative<br>Securities<br>Acquired<br>(A) or<br>Disposed<br>of (D)<br>(Instr. 3,<br>4, and 5) | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) | 7. Title and Amount of<br>Underlying Securities<br>(Instr. 3 and 4) |
|--------------------------------------------------------------------------|--------------------------------------------------------------------|-----------------------------------------|-------------------------------------------------------------|--------------------------------------|--------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|---------------------------------------------------------------------|
|                                                                          |                                                                    |                                         |                                                             | Code                                 | V (A) (D)                                                                                                          | Date<br>Exercisable<br>Expiration<br>Date                      | Title<br>Amount or<br>Number of<br>Shares                           |
| Stock<br>Option<br>(right to<br>buy)                                     | \$ 2.02                                                            |                                         |                                                             |                                      |                                                                                                                    | <u>(3)</u> 01/09/2024                                          | Common<br>Stock,<br>\$0.001<br>par value<br>per share 100,000       |
| Series C-3<br>Non-Voting<br>Convertible<br>Preferred<br>Stock <u>(4)</u> | \$ 1                                                               |                                         |                                                             |                                      |                                                                                                                    | <u>(4)</u> <u>(4)</u>                                          | Common<br>Stock,<br>\$0.001<br>par value<br>per share 237,000       |
| Warrant<br>(right to<br>purchase<br>Common<br>Stock) <u>(4)</u>          | \$ 1.25                                                            |                                         |                                                             |                                      |                                                                                                                    | 01/08/2015 01/08/2020                                          | Common<br>Stock,<br>\$0.001<br>par value<br>per share 118,500       |
| Series C-3<br>Non-Voting<br>Convertible<br>Preferred<br>Stock <u>(5)</u> | \$ 1                                                               |                                         |                                                             |                                      |                                                                                                                    | <u>(5)</u> <u>(5)</u>                                          | Common<br>Stock,<br>\$0.001<br>par value<br>per share 13,000        |
| Warrant<br>(right to<br>purchase<br>Common<br>Stock) <u>(5)</u>          | \$ 1.25                                                            |                                         |                                                             |                                      |                                                                                                                    | 01/08/2015 01/08/2020                                          | Common<br>Stock,<br>\$0.001<br>par value<br>per share 6,500         |
| Stock<br>Option<br>(right to                                             | \$ 0.9                                                             |                                         |                                                             |                                      |                                                                                                                    | <u>(6)</u> 03/20/2023                                          | Common<br>Stock,<br>\$0.001 500,000                                 |

|                                      |         |     |            |                                                       |                        |  |
|--------------------------------------|---------|-----|------------|-------------------------------------------------------|------------------------|--|
| buy)                                 |         |     |            |                                                       | par value<br>per share |  |
| Stock<br>Option<br>(right to<br>buy) | \$ 0.68 | (7) | 12/05/2022 | Common<br>Stock,<br>\$0.001<br>par value<br>per share | 100,000                |  |
| Stock<br>Option<br>(right to<br>buy) | \$ 0.29 | (8) | 05/14/2022 | Common<br>Stock,<br>\$0.001<br>par value<br>per share | 50,000                 |  |

## Reporting Owners

| Reporting Owner Name / Address                                                               | Relationships |           |                         |       |
|----------------------------------------------------------------------------------------------|---------------|-----------|-------------------------|-------|
|                                                                                              | Director      | 10% Owner | Officer                 | Other |
| MILBY RANDY<br>C/O CORMEDIX INC.<br>745 ROUTE 202-206, SUITE 303<br>BRIDGEWATER, NJ US 08807 | X             |           | Chief Executive Officer |       |

## Signatures

Alexander M. Donaldson, with a Power of Attorney for Randy Milby 01/02/2015

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) This purchase of newly issued shares was pursuant to an automatic payroll deduction arrangement with the reporting person.
- (2) The reporting person beneficially owns these securities through his ownership interest in MW Bridges LLC (an entity through which he has voting and investment control).
- (3) The option vested 100% on January 10, 2014.

- (4) On January 8, 2014, the reporting person acquired in a private placement (i) 23,700 shares of the Company's Series C-3 Non-Voting Convertible Preferred Stock, each share is convertible into 10 shares of the Common Stock, \$0.001 par value per share at a conversion price of \$1.00 per share; and (ii) a five-year warrant to purchase Common Stock at an exercise price of \$1.25 per share. The Series C-3 Preferred Stock and the warrants were purchased together at a purchase price of \$10.00 per share for each share of Series C-3 Preferred Stock.

- (5) On January 8, 2014, the reporting person, through his ownership in MW Bridges LLC (an entity through which he has voting and investment control), acquired in a private placement (i) 1,300 shares of the Company's Series C-3 Non-Voting Convertible Preferred Stock, each share is convertible into 10 shares of the Common Stock, \$0.001 par value per share at a conversion price of \$1.00 per share; and (ii) a five-year warrant to purchase Common Stock at an exercise price of \$1.25 per share. The Series C-3 Preferred Stock and the warrants were purchased together at a purchase price of \$10.00 per share for each share of Series C-3 Preferred Stock.

- (6) These options vest based on performance milestones running through December 31, 2014.

- (7) These options vested as follows: (a) fifty percent (50%) on the date of issuance of the CE Mark certification for Neutrolin in Europe, which occurred on July 5, 2013, and (b) fifty percent (50%) on December 31, 2013.

## Edgar Filing: CorMedix Inc. - Form 4

(8) These options vested 100% upon receipt of CE Mark approval for the Company's Neutrolin product candidate on July 5, 2013.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.